Alison C. MacKinnon
0000-0002-7967-4141
Publication & Citation Trends
Publications
156 total
The Anti-fibrotic Effect OFGB0139, a Small Molecule Galectin-3 Inhibitor, in Precision Cut Lung Slices From Idiopathic Pulmonary Fibrosis Tissue
Cited by 0
Semantic Scholar
Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1 OA
Cited by 23
Semantic Scholar
Abstract LB104: Preclinical evaluation of the role of Galectin-1 in tumor immune evasion associated mechanisms using a highly selective Galectin-1 small molecule inhibitor
Cited by 0
Semantic Scholar
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants OA
Cited by 33
Semantic Scholar
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease OA
Cited by 75
Semantic Scholar
GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial.
Cited by 2
Semantic Scholar
CD98 is critical for a conserved inflammatory response to diverse injury stimuli relevant to IPF exacerbations and COVID pneumonitis OA
Cited by 2
Semantic Scholar
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation OA
Cited by 24
Semantic Scholar
Research Topics
Galectins and Cancer Biology
(60)
Peptidase Inhibition and Analysis
(31)
Receptor Mechanisms and Signaling
(20)
Macrophage Migration Inhibitory Factor
(16)
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
(15)
Affiliations
University of Notre Dame
University of Southern California
Synlab Czech (Czechia)
University of South Australia
King's College London